AbbVie is a large pharma headquartered in US. Over the past three years, AbbVie has been involved in 78 licensing and acquisition transactions, with a primary focus on Small Molecules (20 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
8
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving AbbVie in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| age-related diseases platform | Calico Life Sciences | Other | Unknown | co development | Jun 25, 2026 |
| age-related diseases program | Calico | Other | Unknown | co development | Jun 24, 2026 |
| Apogee Therapeutics portfolio (Dupixent competitor / long-acting autoimmune biologics) | Apogee Therapeutics | Antibodies | Phase 3 | acquisition | Jun 22, 2026 |
| APG777 | Apogee Therapeutics | Antibodies | Preclinical | acquisition | Jun 15, 2026 |
| KST-6051 | Kestrel Therapeutics | Small Molecules | Unknown | acquisition | Apr 15, 2026 |
| HSK55718 and HSK51155 | Haisco Pharmaceutical Group | Small Molecules | Preclinical | license | Apr 14, 2026 |
| reproxalap | Aldeyra Therapeutics | Small Molecules | Phase 3 | option | Apr 4, 2026 |
| reproxalap | Aldeyra | Small Molecules | Phase 3 | option | Mar 27, 2026 |
| reproxalap | Aldeyra Therapeutics | Small Molecules | Phase 3 | option | Mar 26, 2026 |
| reproxalap | Aldeyra | Small Molecules | Phase 3 | option | Mar 26, 2026 |
Showing 10 of 16 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where AbbVie is most active based on deal history and clinical trial data.
Key indicators of AbbVie's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
AbbVie has 50 active clinical trials across 5 development phases.
2
Phase 4
8
Unknown
15
Phase 1
21
Phase 2
4
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
AbbVie is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 78 deals over the past three years, AbbVie ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AbbVie include Oncology (31 deals and trials), Ophthalmology (11 deals and trials), Codev Deals (9 deals and trials), and Hematological Malignancies (9 deals and trials). In terms of modality, AbbVie has shown particular interest in small molecules, other, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AbbVie and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AbbVie's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals